Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease
Status:
Active, not recruiting
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
This study consists of two parts. Part A will evaluate the safety and tolerability of
multiple doses of OXB-102 (AXO-Lenti-PD) in participants with Parkinson's disease. Part B
will assess the safety and efficacy of the selected dose of OXB-102 in participants with
Parkinson's disease.